Bio Pharma Dive
MARCH 4, 2024
The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.
Pharmaceutical Technology
MARCH 4, 2024
In late 2023, the Medicines and Healthcare products Regulatory Agency approved Vertex’s Casgevy, which became the inaugural clustered regularly interspaced short palindromic repeats (CRISPR)-based drug for the haematological indications beta thalassemia and sickle cell disease (SCD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 4, 2024
Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal.
Pharmaceutical Technology
MARCH 4, 2024
The EMA has validated the jointly developed TROP2-directed therapy for patients with breast or lung cancer following positive Phase III data.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
MARCH 4, 2024
The updated results show that responses to the drug, which is currently in late-stage testing, deepened with time, helping the company rebound from an earlier setback.
Pharmaceutical Technology
MARCH 4, 2024
For Rare Disease Day, several panels organised by the FDA discussed the importance overcoming accessibility barriers during drug development.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
MARCH 4, 2024
Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, bolstering ophthalmology and biosimilar expertise.
Bio Pharma Dive
MARCH 4, 2024
How are knowledge graphs changing the path of drug discovery?
pharmaphorum
MARCH 4, 2024
Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine in a clinical trial
Fierce Pharma
MARCH 4, 2024
When Pfizer completed its $43 billion buyout of Seagen in December | Less than three months after completing its $43 billion acquisition of Seagen, Pfizer has confirmed a report that it is shutting down construction of a $350 million manufacturing facility in Everett, Washington. The decision will affect 120 employees working on the initial setup of the site, the company said.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to advanced materials last quarter, and how many were granted? Discover the latest information here.
Pharma Times
MARCH 4, 2024
In the UK alone, the aggressive form of cancer affects around 52,000 men every year
Pharmaceutical Technology
MARCH 4, 2024
The China's NMPA has granted approval for CARsgen Therapeutics' NDA for zevorcabtagene autoleucel to treat multiple myeloma.
Pharma Times
MARCH 4, 2024
Around 900,000 people in the UK are affected by the progressive neurodegenerative disease
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
MARCH 4, 2024
FogPharma has secured $145m in a Series E financing round to support the clinical development of its cancer therapy, FOG-001.
Bio Pharma Dive
MARCH 4, 2024
Panalgo’s Meg Richards and Mike Munsell discuss how AI and ML are transforming the healthcare research landscape.
Pharmaceutical Technology
MARCH 4, 2024
The US FDA has granted full approval for Johnson & Johnson's (J&J) RYBREVANT for types of NSCLC.
Fierce Pharma
MARCH 4, 2024
A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.” | A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.
pharmaphorum
MARCH 4, 2024
Explore the future of drug manufacturing with dark factories, robotic and automated facilities that promise efficiency and innovation. Learn how these advancements are shaping a bright future for the pharmaceutical industry.
Fierce Pharma
MARCH 4, 2024
After decades of research into respiratory syncytial virus (RSV), Pfizer and GSK’s groundbreaking vaccines made waves as the first immunizations against the common respiratory illness. | After a preliminary analysis found a potentially higher risk of Guillain-Barré syndrome following RSV vaccination in older adults, GSK and Pfizer said they will conduct further safety studies.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to robotics last quarter, and how many were granted? Discover the latest information here.
pharmaphorum
MARCH 4, 2024
The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan in breast and lung cancer. The EMA has validated the two parallel applications for the drug, also known as Dato-DXd, in adults with previously treated non-small cell lung cancer (NSCLC) and hormone receptor-positive, HER2-negative breast cancer.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to internet of things last quarter, and how many were granted? Discover the latest information here.
Fierce Pharma
MARCH 4, 2024
Aurobindo subsidiary Eugia is back in hot water with the FDA after a recent plant inspection yielded yet another Form 483—this time in India. | Following an inspection of Eugia's injectables facility in Telangana, India, the FDA issued a formal rebuke laying out seven manufacturing observations, parent company Aurobindo said in a recent filing.
Pharmaceutical Technology
MARCH 4, 2024
How many patents did F. Hoffmann-La Roche submit related to cybersecurity last quarter, and how many were granted? Discover the latest information here.
Pharmaceutical Commerce
MARCH 4, 2024
The latest news for pharma industry insiders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Fierce Pharma
MARCH 4, 2024
Johnson & Johnson continues to grow its oncology franchise with a new FDA approval that opens the lung cancer drug Rybrevant to treating certain newly diagnosed patients. | Johnson & Johnson continues to grow its oncology franchise with a new FDA approval that opens the lung cancer drug Rybrevant to treating certain newly diagnosed patients.
pharmaphorum
MARCH 4, 2024
Bayer licenses European rights to BridgeBio's acoramidis, putting some big pharma muscle behind the ATTR cardiomyopathy treatment
Pharmaceutical Technology
MARCH 4, 2024
How many patents did Bayer submit related to robotics last quarter, and how many were granted? Discover the latest information here.
Fierce Pharma
MARCH 4, 2024
After the U.S. | With the counteroffers, the IRA-mandated negotiations period has begun and will continue through August.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
299 
Let's personalize your content